Skip to main content
OpenTrials
Completed

NCT Number: NCT00445718

Natural History Study of Infants With Adrenal Masses Found on Prenatal and/or Neonatal Imaging

This natural history study is collecting health information about infants with adrenal masses found on prenatal and/or neonatal imaging. Gathering information over time from imaging and laboratory tests of infants with adrenal masses may help doctors learn more about the disease and plan the best treatment.

Completed

Looking for future studies?

Notify Me

Key information

Age range

Up to 6 month

Sex eligibility

All sexes

Study type

Observational

Primary location

Royal Children's Hospital, Parkville, Victoria, Australia

Loading trial locations.

About this study

PRIMARY OBJECTIVE:

I. Determine whether nonoperative management of infants with adrenal masses found on prenatal and/or neonatal imaging results in a 3-year survival rate of 95%.

SECONDARY OBJECTIVES:

I. Estimate the percentage of these patients who are spared surgical resection. II. Evaluate the natural history and histology of perinatal adrenal masses. III. Evaluate the tumor biology and histology of prenatal and neonatal neuroblastomas.

IV. Determine the tumor characteristics that are associated with a need for resection.

OUTLINE:

Patients undergo an abdominal CT or MRI scan on weeks 0, 6, and 42 and an abdominal sonogram on weeks 0, 3, 6, 12, 18, 30, 42, 66, and 90. Urinary catecholamine levels are also measured on the same weeks as the abdominal sonogram. Patients with an increase in tumor volume or catecholamine levels undergo sonographic evaluation and urine catecholamine sampling every 3 weeks until stabilization. Patients with a continued increase in catecholamine levels or a 50% increase in tumor volume undergo surgical resection off protocol therapy.

After a patient goes off-observation, they will be monitored every six months for two years, and annually thereafter.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Sonographically identified adrenal mass meeting one of the following criteria:
  • No greater than 16 mL in volume, if solid
  • No greater than 65 mL if at least 25% cystic and does not cross the midline
  • Disease limited to the adrenal gland
  • No evidence of positive contralateral or ipsilateral lymph nodes or other spread outside the adrenal gland by CT scan or MRI
  • No evidence of disease outside the adrenal gland by MIBG scan
  • Negative for tumor cells by bone marrow biopsy, if performed
  • No more than 6 months of age on the date the mass is first identified
  • No prior chemotherapy
  • No prior abdominal surgery

Treatment and study plan

Computed Tomography

Procedure

Other names: tomography, computed

3-Tesla magnetic resonance imaging

Procedure

Other names: 3-Tesla MRI, 3T MRI

Abdominal Sonogram

Procedure

Sonogram of the abdomen area

Primary outcomes

  1. Survival rate

    Time frame: Up to 3 years

    Estimated using the Kaplan-Meier method.

  2. Event-free survival (EFS)

    Time frame: Up to 3 years

    Estimated using the Kaplan-Meier method.

Sponsors and collaborators

Lead sponsor

Children's Oncology Group

Network

Collaborators

  • National Cancer Institute (NCI)

Registry information

Official study title

Perinatal Neuroblastoma: Expectant Observation A Children's Oncology Group Pilot Study

Important dates

Study start
2001
Primary completion
2013
Study completion
2013
First posted
Mar 9, 2007
Registry last updated
Feb 9, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.